Cargando…
A hybrid design for dose‐finding oncology clinical trials
Identifying the maximum tolerated dose (MTD) and recommending a Phase II dose for an investigational treatment is crucial in cancer drug development. A suboptimal dose often leads to a failed late‐stage trial, while an overly toxic dose causes harm to patients. There is a very rich literature on tri...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084431/ https://www.ncbi.nlm.nih.gov/pubmed/35802470 http://dx.doi.org/10.1002/ijc.34203 |